PDCD1 and neoplasm: Due to distinct mechanisms of activation of immune checkpoints on T cells, such asCTLA-4 stimulation in the lymphatic tissue whereas PD-1/PD-L1 activation occurs inthe tumor microenvironment,8 there is rationale for combining CPIs for improved clinical outcomes.